Medications for Acute Coronary Syndromes
KEYWORDS: patients, orally, risk, heparin, pci, day, used, hours, bleeding, given, nitroglycerin, therapy, coronary, use, acs

(LMWH), unfractionated heparin, or bivalirudin is given routinely to patients with acute coronary syndrome unless contraindicated (eg, by active bleeding or planned use of streptokinase or anistreplase). Choice of agent depends on whether revascularization is anticipated, as well as other factors such as patient characteristics, cost, and local practice. Patients at high risk of systemic emboli (eg, atrial fibrillation with CHA2DS2VASc score â‰¥ 2) also require long-term therapy with an oral anticoagulant (eg, warfarin, dabigatran, apixaban, rivaroxaban). Conversion to oral anticoagulants should begin 48 hours after symptom resolution or PCI. Unfractionated heparin Unfractionated heparin is more complicated to use because it requires frequent (every 6 hours) dosing adjustments to achieve an activated partial thromboplastin time (aPTT) 1.5 to 2 times the control value. In patients undergoing angiography, further dosing adjustment is done to achieve an activated clotting time (ACT) of 200 to 250 seconds if the patient is treated with a GP IIb/IIIa inhibitor and 250 to 300 seconds if a GP IIb/IIIa inhibitor is not being given. However, if bleeding develops after catheterization, the effects of unfractionated heparin are shorter and can be reversed (by promptly stopping the heparin infusion and giving protamine sulfate). Low molecular weight heparin The
